Dacomitinib: Potential New EGFR Inhibitor for First-Line NSCLC Dacomitinib: Potential New EGFR Inhibitor for First-Line NSCLC

The investigational second-generation EGFR inhibitor significantly prolonged PFS, but at a cost of higher toxicity compared to gefitinib.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news